白细胞介素评分(ISOLD)在玻璃体视网膜淋巴瘤诊断中的真实世界表现
该回顾性诊断分析在166例因IL-6和IL-10检测接受眼内采样的患者中评估ISOLD评分对玻璃体视网膜淋巴瘤(VRL)的诊断效能。ISOLD评分在房水样本中AUC为0.966(最佳阈值-5.2时敏感度94.4%、特异度96.7%),在玻璃体样本中AUC为1.0,整体优于单独IL-10/IL-6比值;假阴性多见于接受全身糖皮质激素和/或化疗的患者。
要点
- ISOLD评分在房水样本中AUC为0.966,最佳阈值-5.2时敏感度94.4%、特异度96.7%。
- 玻璃体样本中ISOLD评分在阈值0时敏感度95.0%、特异度100%,最佳阈值-2.55时均为100%。
- 假阳性见于水痘-带状疱疹病毒相关眼病,假阴性多见于免疫抑制或接受糖皮质激素/化疗者。
核心结论
- ISOLD评分是常规临床实践中诊断VRL的可靠工具,其性能主要在房水样本中得到验证。
- ISOLD评分通过提供连续概率估计,优于单独使用IL-10/IL-6比值。
- 玻璃体样本需更大样本量才能对ISOLD评分性能得出明确结论,玻璃体细胞学分析仍是确诊VRL的金标准。
研究设计与样本
- 回顾性比较性诊断分析,纳入2017年1月至2019年6月在一家三级VRL转诊中心接受眼内采样检测IL-6和IL-10的166例患者,共183份样本(房水156份、玻璃体27份)。
- VRL组25例(房水18份、玻璃体20份),对照组141例非VRL患者,包括9例无眼部受累的中枢神经系统淋巴瘤患者和132例无淋巴瘤性疾病患者。
- 采用 cytometric bead array 在未稀释眼内样本中检测IL-6和IL-10,按已发表的房水和玻璃体专用公式计算ISOLD评分,并通过ROC曲线分析确定最佳阈值。
主要发现
- 全部183份样本在阈值0时,ISOLD评分总体敏感度86.8%、特异度98.6%、PPV 94.3%、NPV 96.6%。
- 房水样本(n=156)在阈值0时敏感度77.8%、特异度98.6%、PPV 87.5%、NPV 97.1%;ROC最佳阈值-5.2时敏感度94.4%、特异度96.7%、PPV 73.9%、NPV 99.3%、AUC 0.966。
- 玻璃体样本(n=27)在阈值0时敏感度95.0%、特异度100%、PPV 100%、NPV 87.5%;最佳阈值-2.55时敏感度、特异度、PPV、NPV均为100%,AUC 1.0。
- 出现2例假阳性(水痘-带状疱疹病毒相关眼病)和5例假阴性,假阴性主要见于接受全身糖皮质激素和/或化疗的患者。
关键数值与推荐
- ISOLD评分在房水样本中阈值0时敏感度77.8%、特异度98.6%、PPV 87.5%、NPV 97.1%;ROC最佳阈值-5.2时敏感度94.4%、特异度96.7%、PPV 73.9%、NPV 99.3%、AUC 0.966。
- ISOLD评分在玻璃体样本中阈值0时敏感度95.0%、特异度100%、PPV 100%、NPV 87.5%;最佳阈值-2.55时敏感度、特异度、PPV、NPV均为100%,AUC 1.0。
- IL-10/IL-6比值在房水样本(n=150)阈值0.6时敏感度77.8%、特异度93.9%、PPV 63.6%、NPV 96.9%;ROC最佳阈值0.48时敏感度83.3%、特异度93.9%、PPV 65.2%、NPV 97.6%、AUC 0.942。
- IL-10/IL-6比值在玻璃体样本(n=27)阈值1时敏感度80%、特异度100%、PPV 100%、NPV 63.6%;阈值0.195时敏感度、特异度、PPV、NPV均为100%,AUC 1.0。
临床怎么用
- 临床可依据ISOLD评分(基于房水IL-10和IL-6水平)辅助VRL诊断,尤其适用于房水样本。
- 对接受全身糖皮质激素或化疗的免疫抑制患者,需警惕ISOLD评分假阴性可能。
- 玻璃体样本的ISOLD评分性能数据有限,确诊仍需依赖玻璃体细胞学分析。
局限性
- 本研究为回顾性设计,且比较组以房水样本为主,ISOLD评分在玻璃体样本中的结论需更大样本验证。
- 假阳性和假阴性样本量较小,相关影响因素(如免疫抑制状态)需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the real-world diagnostic performance of the Interleukin Score for IntraOcular Lymphoma Diagnosis (ISOLD) score-a probabilistic formula based on absolute intraocular interleukin-10 (IL-10) and IL-6 levels-and to compare it with absolute cytokine thresholds and the IL-10/IL-6 ratio for vitreoretinal lymphoma (VRL) diagnosis. Because the comparison group consists predominantly of patients who underwent anterior chamber paracentesis (ACP), this study primarily assesses ISOLD performance on aqueous humor (AH) samples while providing additional data on vitreous specimens. DESIGN: Retrospective comparative diagnostic analysis. PARTICIPANTS: A total of 166 patients who underwent intraocular sampling for IL-6 and IL-10 measurement at a tertiary VRL referral center between January 2017 and June 2019, yielding 183 samples (156 AH from ACP and 27 vitreous). Furthermore, 25 patients had confirmed VRL (18 AH samples, 20 vitreous samples; 13 had both, 7 vitreous only, and 5 AH only). The comparison group comprised 141 non-VRL patients: 9 patients with confirmed CNS lymphoma without ocular involvement (PCNSL+ non-VRL group, 9 AH only) and 132 patients without lymphomatous disease (non-PCNSL group, 129 AH and 7 vitreous). METHODS: IL-6 and IL-10 were measured in undiluted intraocular samples by cytometric bead array. The ISOLD score was calculated using published formulas specific to AH and vitreous. Diagnostic performance (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV]) was assessed for the ISOLD score and the IL-10/IL-6 ratio, stratified by sample type. Receiver operating characteristic (ROC) curve analysis was performed to identify optimal thresholds. MAIN OUTCOME MEASURES: Sensitivity, specificity, PPV, and NPV of the ISOLD score and the IL-10/IL-6 ratio for VRL diagnosis were reported separately for AH and vitreous samples. RESULTS: At a threshold of 0, the ISOLD score yielded an overall sensitivity of 86.8%, specificity of 98.6%, PPV of 94.3%, and NPV of 96.6% across all 183 samples. For AH samples (n = 156), which constitute most of this data set, sensitivity, specificity, PPV, and NPV were 77.8%, 98.6%, 87.5%, and 97.1%, respectively; the optimal AH threshold by ROC analysis was -5.2, yielding a sensitivity of 94.4%, specificity of 96.7%, PPV of 73.9%, NPV of 99.3%, and an area under the curve (AUC) of 0.966. For vitreous samples (n = 27), performance at a threshold of 0 was 95.0%, 100%, 100%, and 87.5%, respectively; the optimal vitreous threshold was -2.55, yielding 100% sensitivity, specificity, PPV, and NPV, with an AUC of 1.0. Two false positives occurred in varicella zoster virus-associated ocular disease; 5 false negatives were observed, predominantly in patients receiving systemic corticosteroids and/or chemotherapy. The IL-10/IL-6 ratio at a threshold of 0.6 in AH (n = 150) demonstrated a sensitivity of 77.8%, specificity of 93.9%, PPV of 63.6%, and NPV of 96.9%; at a threshold of 1 in vitreous (n = 27), sensitivity, specificity, PPV, and NPV were 80%, 100%, 100%, and 63.6%, respectively. The optimal AH threshold by ROC analysis for the IL-10/IL-6 ratio was 0.48, yielding a sensitivity of 83.3%, specificity of 93.9%, PPV of 65.2%, NPV of 97.6%, and an AUC of 0.942. For vitreous samples, performance at a threshold of 0.195 was 100%, 100%, 100%, and 100%, respectively, with an AUC of 1.0. Bilateral involvement and intermediate uveitis were significantly more frequent in the VRL group (P = .008 and P = .005, respectively). CONCLUSIONS: The ISOLD score is a reliable tool for VRL diagnosis in routine clinical practice, with performance validated primarily on AH samples obtained by ACP. It outperforms the IL-10/IL-6 ratio alone by providing a continuous probabilistic estimate. False-negative results may occur in immunosuppressed patients or those receiving corticosteroids or chemotherapy. A larger vitreous sample would be required to draw definitive conclusions regarding ISOLD performance on this specimen type. Cytological analysis of vitreous samples remains the gold standard for definitive VRL confirmation.
引用
- Chevalier M, Sourdeau E, Garff-Tavernier ML, et al. Performance of the Interleukin Score for IntraOcular Lymphoma Diagnosis Score in the Diagnosis of Vitreoretinal Lymphoma in Clinical Practice. Am J Ophthalmol. 2026. PMID: 42409156. doi:10.1016/j.ajo.2026.06.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。